MitraClip Reduces Renal Function Deterioration

Severe mitral regurgitation is associated to cardiac failure and hospitalization and over time is accompanied by kidney failure, which leads to higher mortality. 

El MitraClip disminuye el deterioro de la función renal

In the COAPT study, in patients with low ejection fraction, MitraClip showed benefits over medical treatment, but there was an important group of people with kidney function deterioration. 

The evolution and benefit of this device in this group had not been yet assessed and at present there is little evidence about it. 

The COAPT trial was analyzed and three groups were established according to glomerular filtration: no renal deterioration when glomerular filtration was ≥60 mL/min/1.73m2; moderate deterioration when it was between 30–,60 mL/min/1.73m2; and severe deterioration when it was30 mL/min/ 1.73 m2

In addition, there were 37 patients (6.1%) on dialysis. 13 of these patients received MitraClip and 24 optimal medical treatment at maximum tolerated dose. 

They looked at 606 patients, 144 presenting severe deterioration (23.8%), 323 moderate deterioration (53.3%) and 139 no renal deterioration (22.9%).

Read also: Revascularization Using DES in Infrapopliteal Disease: Meta-Analysis and Change of Paradigm?

Patients with moderate and severe deterioration were older, had more comorbidities (diabetes, coronary artery disease, ischemic cardiomyopathy, anemia) higher NT-proBNP elevation, and higher surgical risk. 

At 2-year followup, baseline renal function deterioration was associated to higher mortality or hospitalization for cardiac failure (p<0.0001). In addition, both mortality and rehospitalization were higher when analyzed separately. Patients on dialysis presented a 68.7% rate of death and hospitalization for cardiac failure and 33.4% rate of hospitalization for cardiac failure. 

MitraClip reduced renal function deterioration (P Interaction=0.62) vs. complete medical treatment at maximum tolerated dose, reduced renal function deterioration onset [2.9 vs. 8.1%, hazard ratio (HR) 0.34, 95% confidence interval (CI) 0.15–0.76, P=0.008] and the need for dialysis (2.5 vs. 7.4%, HR 0.33, 95% CI 0.14–0.78, P=0.011).

Conclusion

Kidney function deterioration in patients with cardiac failure with mitral regurgitation enrolled in the COAPT study is a strong predictor of death and hospitalization for cardiac failure at 2 years. MitraClip reduces kidney deterioration onset and the need for dialysis, contributing to improving prognosis after percutaneous repair of the mitral valve. 

Dr. Carlos Fava - Consejo Editorial SOLACI

Dr. Carlos Fava.
Member of the Editorial Board of SOLACI.org.

Original Title: Impact of baseline renal dysfunction on cardiac outcomes and end-stage renal disease in heart failure patients with mitral regurgitation: the COAPT trial.

Reference: Nirat Beohar, et al. European Heart Journal (2022) 43, 1639–1648.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

Prospective Analysis of the Feasibility of the PASCAL System for Transcatheter Mitral Repair: OneForAll Registry

Courtesy of Dr. Juan Manuel Pérez. Mitral transcatheter edge-to-edge repair (M-TEER) is an effective option for patients with severe mitral regurgitation who are at high...

Left Bundle Branch Block after TAVR: What Is Its Impact?

Courtesy of Dr. Juan Manuel Pérez. Left bundle branch block (LBBB) is a common complication following transcatheter aortic valve replacement (TAVR), which can be either...

Multicenter Experience with 3D Intracardiac Echocardiography for Guiding Interventional Cardiac Procedures

Courtesy of Dr. Juan Manuel Pérez. Imaging techniques play a fundamental role in interventional cardiac procedures. Intracardiac echocardiography (ICE) appears as an alternative to transesophageal...

Pathology of Self-Expanding Transcatheter Aortic Bioprostheses and Hypoattenuated Leaflet Thickening

Courtesy of Dr. Juan Manuel Pérez. Despite the available long term followup data on of transcatheter aortic valve replacement (TAVR), bioprosthesis durability continues under debate....

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACC 2025 | FAME 3: FFR Guided PCI vs CABG 5 Year Outcomes.

Earlier studies comparing percutaneous coronary intervention (PCI) vs coronary artery bypass graft (CABG) have shown fewer events at long term for the surgical strategy.  However,...

ACC 2025 | API-CAT: Reduced vs. Full Dose Extended Anticoagulation in Patients with Cancer Related VTE

The risk of cancer related recurrent venous thromboembolism (VTE) will drop over time, while bleeding risk will persist. At present, it is recommended we...

STRIDE: Semaglutide in Patients with Peripheral Arterial Disease and Type II Diabetes

Peripheral arterial disease (PAD) is a severe complication in patients with type II diabetes, primarily affecting peripheral vessels, especially below-the-knee (BTK) arteries. This condition...